Today: 11 June 2026
Realty Income (O) today: 665th monthly dividend, new 150M‑share ATM filing, and fresh Q3 2025 takeaways (Nov 8, 2025)
8 November 2025
2 mins read

Realty Income (O) today: 665th monthly dividend, new 150M‑share ATM filing, and fresh Q3 2025 takeaways (Nov 8, 2025)

Realty Income Corporation (NYSE: O), “The Monthly Dividend Company,” capped a busy week with two investor‑focused updates now resonating today: the REIT’s 665th consecutive monthly dividend and a new at‑the‑market (ATM) equity program authorizing the sale of up to 150 million shares. The headlines land just days after Q3 results and a modest guidance tweak. PR Newswire+1


Dividend at a glance

  • Amount:$0.2695 per share (annualized $3.234)
  • Record date:Nov. 28, 2025
  • Payment date:Dec. 15, 2025
  • Streak:665 consecutive monthly dividends

At Friday’s close near $56.9, the declared payout implies a forward yield around the mid‑5% range, underscoring why Realty Income remains a staple for income‑focused investors.


Capital move: New 150M‑share ATM program

Realty Income filed an 8‑K on Friday detailing a new sales agreement that allows the company to sell up to 150,000,000 common shares from time to time—directly, via agents, or through forward sale agreements. The filing notes the prior 2024 ATM was terminated concurrently; of its original 120 million shares, 65,033,051 had been sold. Proceeds from the new ATM may fund debt repayment, acquisitions/development, hedging, and other general corporate purposes.


Q3 scorecard and guidance: steady operations, active investing

Earlier this week, Realty Income reported Q3 2025 AFFO of $1.08 per share and FFO of $1.07 per share, with revenue at ~$1.47B. The company updated 2025 AFFO guidance to $4.25–$4.27 and lifted its full‑year investment volume outlook to ~$5.5B. Management highlighted a 103.5% rent recapture rate on re‑leased properties, $1.4B invested during the quarter at a 7.7% initial cash yield, and 98.7% portfolio occupancy across 15,542 properties with a weighted average remaining lease term of ~8.9 years. Net debt to annualized pro forma Adjusted EBITDAre stood at 5.4x as of quarter‑end.

Reuters summarized the outlook shift as a narrow/tightened 2025 adjusted FFO range of $4.25–$4.27 per share, reflecting resilience even as rate and capital markets stay in focus.


Why today’s updates matter

  • Income continuity: Another monthly dividend—now in its 665th iteration—reinforces Realty Income’s brand promise to income investors.
  • Balance‑sheet flexibility: The new ATM capacity gives management optionality to match equity issuance with accretive investments or de‑leveraging as opportunities and market windows emerge. The use of forward sales can time settlement with pipeline deployment, tempering immediate dilution.
  • Operational health:High occupancy, positive re‑leasing economics (103.5% recapture), and an active acquisition engine—especially in Europe—continue to underpin internal and external growth.

Analyst and market context (today)

  • RBC Capital this week raised its price target to $61 and kept an Outperform rating following the company’s Q3 update.
  • A Yahoo Finance valuation brief published today notes shares around the high‑$56s versus a fair‑value estimate in the low‑$60s, suggesting room for upside if assumptions hold.
  • Coverage today from GuruFocus framed the quarter as in line on earnings with a revenue beat and emphasized the 103.5% rent recapture and ongoing international investment activity.

Key numbers to know

  • Dividend: $0.2695 per share (Dec. 15 payable; Nov. 28 record).
  • ATM program: Up to 150,000,000 shares; prior ATM terminated after 65,033,051 shares sold; proceeds for corporate uses including debt repayment and acquisitions.
  • Q3 metrics:AFFO $1.08, FFO $1.07, Revenue ~$1.47B, Recapture 103.5%, Investment $1.4B @ 7.7%, Occupancy 98.7%, WALT ~8.9 years.
  • 2025 guide (updated):AFFO $4.25–$4.27; investment volume ~$5.5B.

What to watch next

  1. ATM utilization pace: Management’s cadence in issuing shares—especially via forward sales—versus acquisition timing and debt paydowns.
  2. Deal flow and yields: Whether Q3’s 7.7% initial cash yield on investments and elevated European activity continue into Q4.
  3. Rent recapture and occupancy: If the >100% recapture trend and ~99% occupancy hold as 2025 winds down.

Bottom line

For Nov. 8, 2025, Realty Income’s news flow centers on dividend dependability and funding flexibility. Pairing an ongoing monthly payout with a fresh, large‑scale ATM program positions the REIT to keep investing while managing leverage—an approach consistent with its Q3 operating momentum and slightly refined 2025 guidance.

This article is for informational purposes only and does not constitute investment advice.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Theriva Biologics Shares Surge 75% on VCN-01 Phase 1 Cancer Trial Data
    June 11, 2026, 11:01 AM EDT. Theriva Biologics' stock (TOVX) jumped 74.6% after publication of Phase 1 trial results for its cancer drug VCN-01 in Clinical Cancer Research. The study targeted head-and-neck squamous cell carcinoma, showing median overall survival between 10.3 and 17.3 months across dosing groups. VCN-01 is an oncolytic adenovirus designed to break down tumor cells and enhance immune checkpoint inhibitor efficacy, used alongside AstraZeneca's durvalumab. Biomarker data confirmed immune activation signals, suggesting VCN-01 may resensitize tumors to treatment. Despite the rally, risks remain including financing, dilution, and clinical trial execution. Theriva's market cap stayed under $20 million amid high trading volumes, reflecting investor interest in immuno-oncology advances.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
IBM Stock Soars on Quantum Breakthrough and AI Revival – Key Updates (Sept 25, 2025)
Previous Story

IBM Stock Today (Nov. 7, 2025): Shares Slip 1.9% as Dow Weakens; DARPA Quantum Milestone and Red Hat Integration Dominate the Headlines

Anduril’s Fury (YFQ‑44A) Completes First Flight in 556 Days, Accelerating the Air Force’s CCA Program — What’s New Today (Nov. 10, 2025)
Next Story

Anduril’s Fury (YFQ‑44A) Completes First Flight in 556 Days, Accelerating the Air Force’s CCA Program — What’s New Today (Nov. 10, 2025)

Go toTop